anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective: To explore the clinical efficacy of posterior femoral muscle flaps combined with posterior femoral cutaneous nerve nutrient vessel flap and closed lavage in the treatment of stage Ⅳ ischial tuberosity pressure ulcers. Methods: This study was a retrospective observational study. From March 2021 to March 2022, 15 patients with stage Ⅳ ischial tuberosity pressure ulcers who met the inclusion criteria were admitted to Dezhou Dongcheng Hospital, including 11 males and 4 females, aged 31 to 72 years. The pressure ulcer wound size ranged from 6.0 cm×4.5 cm to 10.0 cm×6.0 cm, with cavity diameters of 10-14 cm. Five cases were complicated with ischial tuberosity bone infection. After clearing the lesion, the biceps femoris long head muscle flap with an area of 10.0 cm×4.0 cm-18.0 cm×5.0 cm and the semitendinosus muscle flap with an area of 8.0 cm×4.0 cm-15.0 cm×5.0 cm combined with the posterior femoral cutaneous nerve nutrient vessel flap with an area of 6.5 cm×5.5 cm-10.5 cm×6.5 cm was transplanted to repair the pressure ulcer wound. The flap donor area was directly sutured, and the closed lavage with tubes inserted into the wound cavity was performed for 2-3 weeks. The postoperative survival of the muscle flaps and skin flaps, the wound healing of the donor and recipient areas were observed. The recurrence of pressure ulcers, the appearance and texture of flaps, and scar conditions of the donor and recipient areas were followed up. Results: All the muscle flaps and skin flaps in the 15 patients successfully survived after surgery. Two patients experienced incisional dehiscence at one week after surgery due to improper turning over, during which the incision in the recipient area was pressed on, and the wounds healed after dressing changes of 3 to 4 weeks; the wounds in the donor and recipient areas healed well in the other patients. All patients received follow-up after surgery. During the follow-up period of 6 to 12 months, none of the patients experienced pressure ulcer recurrence, and the texture, color, and thickness of the skin flaps closely resembled those of the surrounding skin at the recipient site, with only linear scar left in the donor and recipient areas. Conclusions: When using the posterior femoral muscle flaps combined with the posterior femoral cutaneous nerve nutrient vessel flap and closed lavage to treat stage Ⅳ ischial tuberosity pressure ulcers, the tissue flap can be used to fully fill in the dead space of the pressure ulcers. After treatment, the wound heals well, the appearance of the donor and recipient areas is better, and the pressure ulcers are less prone to reoccur.
The expected signs and symptoms with overdosage of SEREVENT DISKUS are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the following: seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia. Overdosage with SEREVENT DISKUS can lead to clinically significant prolongation of the QTc interval, which can produce ventricular arrhythmias. Other signs of overdosage may include hypokalemia and hyperglycemia.

As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of SEREVENT DISKUS.

Treatment consists of discontinuation of SEREVENT DISKUS together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of SEREVENT DISKUS. Cardiac monitoring is recommended in cases of overdosage.

No deaths were seen in rats given salmeterol at an inhalation dose of 2.9 mg/kg (approximately 240 and 110 times the MRHD for adults and children, respectively, on an mg/m2 basis) and in dogs at an inhalation dose of 0.7 mg/kg (approximately 190 and 90 times the MRHD for adults and children, respectively, on an mg/m2 basis). By the oral route, no deaths occurred in mice at 150 mg/kg (approximately 6,100 and 2,900 times the MRHD for adults and children, respectively, on an mg/m2 basis) and in rats at 1,000 mg/kg (approximately 81,000 and 38,000 times the MRHD for adults and children, respectively, on an mg/m2 basis).
A method for identifying blood donor information using a personal digital assistant and an apparatus using the same are provided to enhance business efficiency by performing automatically a verification process. A blood donor paperweight process is performed(S10). Paperweight information and blood donor bar code information are transmitted to a server computer(S20). The server computer stores corresponding information into a database(S30). A bar code is scanned to identify blood donor information and is transmitted to the server computer(S40). The server computer provides the corresponding blood donor information(S50). A blood-gathering process is performed when the corresponding blood donor information is identified(S60,S80). The bar code is scanned to identify the blood donor information and is transmitted to the server computer(S90). The server computer provides the corresponding blood donor information(S100). The corresponding blood donor information is identified(S110).
CVD is a disorder that affects the heart's ability to function normally. The most common cause of heart disease is narrowing or blockage of the coronary arteries, which supply blood to the heart. There are many risk factors for CVD, including inflammation, high blood pressure, high cholesterol, and obesity. Small quantities of trace elements, also known as micronutrients, are essential in maintaining a healthy body. Research has shown that some trace elements may be associated with the development of CVD, but more research is needed to confirm this connection. This study will examine concentrations of several trace elements in toenail samples of young adults participating in the Coronary Artery Risk Development in Young Adults (CARDIA) study. The CARDIA study is measuring changes in CVD risk factors in individuals as they age and is identifying lifestyle habits that influence those changes. The purpose of this study is to determine the link between trace elements and CVD risk factors in young adults. The results of this study may help to identify whether dietary, lifestyle, or environmental factors can be modified at a young age to prevent the development of CVD.

This study will examine laboratory and medical history data of participants who are already enrolled in the CARDIA study; there are no additional study visits specifically for this study. Toenail samples collected from participants during their Year 2 CARDIA study visit in the late 1980's will be examined to determine the presence of selenium, chromium, arsenic, and mercury. Participants' CARDIA study data will be reviewed and several CVD risk factors will be analyzed, including the thickness of heart arteries; calcium buildup within the arteries; inflammatory markers, such as high sensitivity C-reactive protein and interleukin 6; blood pressure levels; body weight; and levels of cholesterol, fat, and sugar.
Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.
The invention relates to an externally applied traditional Chinese medicine composition for treating umbilical hernia and an umbilical hernia treating bag containing lychee seed and rhizoma cimicifugae. The traditional Chinese medicine composition is prepared from radix astragali, angelica, bighead atractylodes rhizome, rhizoma cimicifugae, radix bupleuri, dried orange peel, toosendan fruit, Evodia rutaecarpa, lychee seed, fennel, clove, asarum, safflower and the like. The umbilical hernia treating bag comprises a bellyband body and fastening belts, wherein the inner side of the bellyband body is provided with a square or circular inner bag, and a medicine core pad containing the traditional Chinese medicine composition is filled in the inner bag. In the invention, traditional Chinese medicines with the functions of tonifying middle-Jiao and qi, soothing the liver and strengthening the spleen are used for umbilical skin absorption and physical support for treating infantile umbilical hernia. By utilizing the externally applied traditional Chinese medicine composition, the defect of long treatment course in self-recovery and conservative treatment of umbilical hernia and the defect that the sick children can feel painful in the operative treatment are solved. The invention has the characteristics of obvious curative effect and short treatment course, and the patients can not feel painful and have no skin irritation symptom or anaphylaxis. The invention is suitable for children with tender viscera, is also suitable for clinical features of children, and can promote the children with umbilical hernia to grow up healthily. The raw materials in the prescription are conventional traditional Chinese medicines, thus, the invention has the advantages of wide raw material sources, low cost and simple technique, and is easy for popularization.
Based on animal studies, AUVELITY may cause fetal harm when administered during pregnancy. In developmental toxicity studies in rats and rabbits, when a combination of dextromethorphan/quinidine was given to pregnant animals, fetal malformations (rabbits) and embryolethality were demonstrated in offspring. Neurotoxicity findings were observed in juvenile rats treated with a combination of dextromethorphan/quinidine on postnatal day (PND) 7, which corresponds to the third trimester of gestation through the first few months of life and may extend through the first three years of life in humans. The separate effect of dextromethorphan on developmental toxicity at the recommended clinical dose is unclear. Discontinue treatment in pregnant females and advise the patient about the potential risk to a fetus. Use alternative treatment for females who are planning to become pregnant [see Use in Specific Populations (8.1, 8.3)].
UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
BACKGROUND: The essential function of HBV DNA polymerase (HBV-DNA-Pol) is to initiate viral replication by reverse transcription; however, the role of HBV-DNA-Pol in HBV-associated HCC has not been clarified. Glycogen phosphorylase L (PYGL) is a critical regulator of glycogenolysis and is involved in tumorigenesis, including HCC. However, it is unknown whether HBV-DNA-Pol regulates PYGL to contribute to HCC tumorigenesis.
METHODS: Bioinformatic analysis, real-time quantitative PCR, western blotting, and oncology functional assays were performed to determine the contribution of HBV-DNA-Pol and PYGL to HCC development and glycolysis. The mechanisms of co-immunoprecipitation and ubiquitination were employed to ascertain how HBV-DNA-Pol upregulated PYGL.
RESULTS: Overexpression of HBV-DNA-Pol enhanced HCC progression in vitro and in vivo. Mechanistically, HBV-DNA-Pol interacted with PYGL and increased PYGL protein levels by inhibiting PYGL ubiquitination, which was mediated by the E3 ligase TRIM21. HBV-DNA-Pol competitively impaired the binding of PYGL to TRIM21 due to its stronger binding affinity to TRIM21, suppressing the ubiquitination of PYGL. Moreover, HBV-DNA-Pol promoted glycogen decomposition by upregulating PYGL, which led to an increased flow of glucose into glycolysis, thereby promoting HCC development.
CONCLUSIONS: Our study reveals a novel mechanism by which HBV-DNA-Pol promotes HCC by controlling glycogen metabolism in HCC, establishing a direct link between HBV-DNA-Pol and the Warburg effect, thereby providing novel targets for HCC treatment and drug development.
Cells that produce inventive pseudotyped retroviruses having a broad host range have been produced. In one aspect of the invention, the cells produce retroviruses pseudotyped with at least two different viral glycoproteins, such as togaviral glycoproteins. In alternative embodiments, the cells produce retroviruses pseudotyped with filoviral glycoproteins. Methods of producing the above-described cells, as well as the pseudotyped retroviruses thus produced, are also provided. In other embodiments, methods of screening agents effective in blocking viral entry into a cell, including filoviral entry or entry of viruses having at least two different viral glycoproteins disposed in their lipid bilayer, such as togaviruses, are provided. Moreover, methods of using the inventive pseudotyped retroviruses for introducing nucleotide sequences into target cells, and kits for forming the inventive pseudotyped retroviruses, are also provided.
AKG, a central metabolite in the Krebs cycle, plays a vital role in cellular energy production and nitrogen metabolism. This review explores AKG's potential therapeutic applications in skeletal muscle health and exercise performance, focusing on its mechanisms for promoting muscle regeneration and counteracting muscle atrophy. A literature search was conducted using the PubMed, Web of Science, and Scopus databases, yielding 945 articles published up to 31 October 2024. Of these, 112 peer-reviewed articles met the inclusion criteria and formed the basis of this review. AKG supports muscle recovery by stimulating muscle satellite cells (MuSCs) and macrophage polarization, aiding muscle repair and reducing fibrosis. Additionally, AKG shows promise in preventing muscle atrophy by enhancing protein synthesis, inhibiting degradation pathways, and modulating inflammatory responses, making it relevant in conditions like sarcopenia, cachexia, and injury recovery. For athletes and active individuals, AKG supplementation has enhanced endurance, reduced fatigue, and supported faster post-exercise recovery. Despite promising preliminary findings, research gaps remain in understanding AKG's long-term effects, optimal dosage, and specific pathways, particularly across diverse populations. Further research, including large-scale clinical trials, is essential to clarify AKG's role in muscle health and to optimize its application as a therapeutic agent for skeletal muscle diseases and an enhancer of physical performance. This review aims to provide a comprehensive overview of AKG's benefits and identify future directions for research in both clinical and sports settings.
Disclosed are nucleic acid preserving compositions and methods of manufacturing and using the same, particularly for detection of COVID-19 virus. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. Compositions as aqueous solutions can include water as a carrier. Preferred embodiments include water, guanidine thiocyanate, Tris, EDTA, SLS, SDA 3C, HCl, and N-acetyl-L-cysteine. Some embodiments include a colored dye as a visual indicator. Kits include the composition disposed in a portion of a biological sample collection apparatus. Methods of manufacturing include combining the components into a mixture, such as an aqueous solution. Methods of use include providing a biological sample that includes nucleic acid and contacting the biological sample with the composition. Detection of COVID-19 virus is demonstrated. Compositions also preserve and stabilize human nucleic acid for subsequent analysis.
Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
Background: Aerococcus urinae and Aerococcus sanguinicola are emerging pathogens linked with urinary tract infections. We present a case series of A. urinae and A. sanguinicola isolates characterizing the spectrum of clinical presentation, microbiological characteristics and antimicrobial sensitivities.Methods: Retrospective chart review was performed on patients who grew positive cultures for A. urinae and A. sanguinicola identified on MALDI-TOF in Saskatchewan from January to June 2023. Demographic and clinical variables, antimicrobial susceptibility and prescription were documented.Results: This cohort (n = 115) had a median age 82 years. A. urinae and A. sanguinicola infections spanned from urinary tract infection (n = 96) to urosepsis (n = 6). These infections were predominantly monomicrobial (73.9%) and were susceptible to ceftriaxone, penicillin G and vancomycin. Antimicrobials were seldom prescribed within the urinary tract infection cohort (31.2%).Conclusion: Untreated A. urinae and A. sanguinicola infections can precipitate into urosepsis. The reported antimicrobial susceptibility for these Aerococcus isolates should be utilized to provide appropriate antimicrobial coverage.
The invention discloses Jiashu swelling eliminating powder. The liver cirrhosis ascites shall be treated by tonifying spleen and kidney, removing blood stasis and removing the symptoms, and inducing diuresis to alleviate edema. The technical scheme of the invention is to adopt the medicine in the following mixing ratio: 6 percent of radix bupleuri, 4 percent of capillary artemisia, 4 percent of salvia miltiorrhiza, 3 percent of curcuma zedoary, 8 percent of roasted rhizoma atractylodis macrocephalae, 3 percent of Dangshen, 4 percent of roasted astragalus root, 3 percent of herba epimedii, 8 percent of vinegar turtle shell, 5 percent of deer-horn gelatin, 3 percent of rhizoma curculiginis, 4 percent of glossy privet fruit, 6 percent of pericarpium arecae, 6 percent of grifola, 6 percent of tuckahoe, 6 percent of rhizoma alismatis, 4 percent of root of common peony, 3 percent of trigone, 4 percent of rhizoma corydalis, 4 percent of curcuma aromatica, 4 percent of lalang grass rhizome and 2 percent of winterworm summerherb. The 22 types of traditional Chinese medicine are crushed to be super-fine, uniformly mixed and prepared into powder or pills. A patient can take 10g to 15g every time when having ascites, and the powder shall be taken with boiled water after meals for three times a day. Afterwards, the patient can take 5g to 10g of the powder every time, and the powder shall also be taken with boiled water after meals for three times a day. Generally, the conditions of the patient turn better after the powder is taken for a month.
NEW MATERIAL:The compound (salt) of formula (X is Phe or Tyr). USE:A remedy for diseases in which bone metabolism is participated. PREPARATION:The peptide derivative can be produced e.g. by dividing the amino acid sequence of a peptide into two blocks, synthesizing each peptide block successively according to the amino acid sequence and bonding the synthesized blocks with each other. Concretely, a rat parathormone (r-PTH) peptide derivative wherein Met at 8- and 21-sites are substituted with L-norleucine can be produced by dissolving a C-terminal amino acid phenacyl ester of each peptide e.g. in dimethylformamide, repeating the steps to bond an amino- protected amino acid to the peptide according to the amino acid sequence and to remove the amino-protecting group from the product and bonding two peptides synthesized by the above process with each other.
The questionnaire contained questions regarding the respondents'information, including their gender, years in practice, clinical specialty,and source of knowledge on immunization practices. The questionnaire mainly contained three sections: knowledge of vaccinations for hepatitis A virus (HAV), HBV, and varicella; current vaccination practices for the IBD group; and reasons for not recommending these vaccinations to patients with IBD. The questionnaire composed of 13 items specifically on the three vaccinations mentioned above for immunosuppressed patients with IBD. All questions were conducted based on recognized guidelines and were reviewed by 18 IBD experts. The questionnaire captured the frequency with which the respondents assessed patients with IBD for anti-HAV/hepatitis B surface antigen (HBsAg), hepatitis B core antibody, and hepatitis B surface antibody/ anti-HAV levels, and acquired infection and immunization histories. Whether the respondents recommended these three vaccines to the IBD group before treatment was also elicited.
Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.
Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
Using the EOS calculator application between 0-24 hours after birth, maternal EOS risk factors combined with the physical examination of the newborn are used to assign a risk category and accompanying clinical recommendation based on estimated EOS incidence for each newborn at-risk for an infection. The EOS calculator results are used to guide clinical management on performing either a diagnostic work-up and start of antibiotics for (suspected) EOS, or a conservative approach with routine controls of vital parameters every 3 hours. In case of routine controls, re-evaluation of physical appearance by a pediatric resident or pediatrician will take place within 24 hours postpartum. Newborns will be observed for at least 24 hours. In case antibiotics are started, the need for further treatment is depending on blood culture results, infection parameters, and clinical condition of the newborn. Discontinuation of antibiotics and discharge is at the discretion of the treating physician.